<DOC>
	<DOC>NCT00608153</DOC>
	<brief_summary>The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.</brief_summary>
	<brief_title>Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>essential hypertension under candesartan treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>ARB</keyword>
	<keyword>compliance</keyword>
	<keyword>candesartan</keyword>
</DOC>